Aurobindo Pharma’s Unit-VII classified as ‘Voluntary Action Indicated’ by US FDA

Business Desk — Wed, 06 May 2026 03:43:02 +0000

Aurobindo Pharma’s Unit-VII, an oral solid dosage manufacturing unit located in Jedcherla, Telangana, has been classified as ‘Voluntary Action Indicated’ (VAI) by the United States Food and Drug Administration (US FDA). This classification follows an inspection conducted by the US FDA from January 28 to February 10, 2026.

During the inspection, the US FDA issued a ‘Form 483’ with a total of nine observations. A ‘Form 483’ is a document used by the FDA to notify a company of any objectionable conditions observed during an inspection. The issuance of this form indicates that the FDA has identified certain areas that require corrective action.

The recent receipt of the Establishment Inspection Report (EIR) signifies that the inspection is now closed. The ‘Voluntary Action Indicated’ classification suggests that while the FDA has identified issues, they are not significant enough to warrant regulatory action. Instead, the company is expected to take voluntary corrective measures.

The inspection and subsequent classification are part of the FDA’s routine oversight to ensure compliance with regulatory standards in the pharmaceutical industry. Aurobindo Pharma will likely address the observations noted in the ‘Form 483’ to align with FDA expectations.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Jedcherla | Business Upturn

Aurobindo Pharma’s Unit-VII classified as ‘Voluntary Action Indicated’ by US FDA